Fourth clinical trial opened with monalizumab (IPH2201)
Number of shares and voting rights of Innate Pharma as at December 7, 2015
First patient dosed in Phase I trial of IPH4102
New combination trial with lirilumab in hemato-oncology
Third Quarter 2015 Report
Innate Pharma receives development milestone payment from Bristol-Myers Squibb
Opening of the Phase I/II trial of IPH2201 in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia
First patient treated in phase I/II trial with IPH2201 in ovarian cancer
Presentation of IPH4102 rationale and phase I design at the cutaneous lymphoma task force meeting of the EORTC
First half of 2015: landmark agreement with AstraZeneca and strong financial position
